Murepavadin
Also known as: Murepavadin, POL7080, RG7929
Source Murepavadin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Murepavadin (also known as POL7080 or RG7929) is an investigational cyclic peptidomimetic antibiotic that selectively targets Pseudomonas aeruginosa. Developed for serious respiratory infections such as hospital‑acquired bacterial pneumonia and ventilator‑associated bacterial pneumonia, it belongs to a novel class of outer‑membrane protein‑targeting agents. Early clinical studies have explored both intravenous and inhaled delivery, aiming to address multidrug‑resistant (MDR) and extensively drug‑resistant (XDR) P. aeruginosa strains that limit current therapeutic options.
Mechanism of Action
Murepavadin is a pathogen‑specific peptidomimetic that binds to an essential outer‑membrane protein of P. aeruginosa, disrupting the integrity of the bacterial envelope without causing cell lysis. This non‑lytic interaction impairs the bacterium’s ability to maintain its outer membrane, leading to rapid bacterial death. By targeting a protein unique to P. aeruginosa, the compound offers a high degree of selectivity and reduces the likelihood of off‑target effects on human cells or commensal flora.
What the Research Shows
Reviews of emerging anti‑pseudomonal agents list murepavadin as a promising candidate for MDR/XDR infections, particularly ventilator‑associated pneumonia. Phase‑1 pharmacokinetic studies in healthy volunteers demonstrated dose‑proportional, linear exposure with a half‑life of 2.5–5.3 hours and good tolerability; no dose‑limiting toxicities were observed. A separate single‑dose study in subjects with varying renal function showed that impaired clearance increased AUC 2‑ to 2.5‑fold and prolonged half‑life up to 24 hours, indicating the need for renal dose adjustment. Across studies, adverse events were mild and transient, supporting a favorable early safety profile, though efficacy data in infected patients remain pending.
Reported Benefits
Murepavadin’s narrow spectrum focuses on P. aeruginosa, offering potent activity against strains resistant to multiple existing classes, including carbapenems and β‑lactam/β‑lactamase inhibitor combinations. Its novel outer‑membrane target reduces cross‑resistance with other antibiotics. Early human trials report good tolerability and predictable pharmacokinetics, suggesting feasibility for both systemic and inhaled administration in severe respiratory infections where high local drug concentrations are advantageous.
Limitations of the Evidence
Evidence is limited to phase‑1 healthy‑volunteer and renal‑impairment studies; no phase‑2 or phase‑3 efficacy trials have been published, so clinical benefit in actual infections remains unproven. The need for dose adjustment in renal impairment adds complexity. As an investigational agent, regulatory approval has not been granted, and long‑term safety, resistance development, and real‑world effectiveness are still unknown.
Safety Considerations
Across early trials, murepavadin was well tolerated, with only mild, transient adverse events such as headache or gastrointestinal discomfort reported. No serious adverse events or dose‑limiting toxicity occurred. Renal impairment markedly increased systemic exposure, necessitating dose reduction to avoid potential toxicity. Ongoing monitoring for unforeseen safety signals is warranted as development progresses.
How It Is Administered
Murepavadin has been evaluated as an intravenous infusion (e.g., a single 2.2 mg/kg dose administered over three hours) and is also being investigated for inhaled delivery to the lungs. Formulations suitable for nebulization are under development to target ventilator‑associated pneumonia, while the IV formulation supports systemic treatment of severe infections.
Routes of Administration
Goals & Uses
- Treatment of MDR/XDR Pseudomonas aeruginosa infectionsAntibacterial Therapy – Resistant PathogensModerate
- Inhaled therapy for pulmonary P. aeruginosa (e.g., cystic fibrosis)Infectious Disease / PulmonaryLow
- Treatment of Pseudomonas aeruginosa bloodstream infectionsAntibacterial TherapyModerate
- Ventilator-associated bacterial pneumonia (VABP)Infectious Disease / Critical CareModerate
- Hospital-acquired bacterial pneumonia (HABP)Infectious Disease / PulmonaryModerate
- Treatment of Pseudomonas aeruginosa infectionsAntibacterial TherapyModerate
- Ventilator‑associated pneumonia caused by P. aeruginosaAntibacterial TherapyModerate
Contraindications
- Known hypersensitivity to murepavadin or peptidomimetic componentsAllergy/ImmunologyHigh
- Severe pre-existing renal impairmentRenalHigh
- Severe renal impairmentOrganHighKidney function concerns
- Concurrent use of nephrotoxic agentsDrug Interaction / RenalHigh
- Known hypersensitivity to murepavadin or its excipientsAllergyModerate
Adverse Effects
- Acute kidney injury / NephrotoxicityRenalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Acute kidney injuryRenalUnknownSudden decline in kidney function
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Elevated serum creatinineRenal / LaboratoryUncommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Infusion-related reactionsHypersensitivityCommon
Drug Interactions
- Aminoglycosides (e.g., tobramycin, amikacin)High
- Concurrent nephrotoxic agents (e.g., aminoglycosides, vancomycin)High
- VancomycinHigh
- NSAIDsModerateMay increase renal risk in susceptible patients
- Colistin / Polymyxin BHigh
Population Constraints
- Patients with pre-existing renal impairmentOrgan FunctionRelative
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionInvestigationalNo EMA approval; development halted.
- United StatesInvestigationalPhase II discontinued; no FDA approval.
- United KingdomInvestigationalNo MHRA approval; investigational only.
Development discontinued after reports of acute kidney injury; no regulatory approval in any jurisdiction.
Evidence & Sources
- Journal ArticleModerateHorcajada JP, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleModerateBassetti M, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleModerateRomanos LT, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateDale GE, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleModerateWach A, Dembowsky K, Dale GE2018-01-01T00:00:00.000000Z
- Journal ArticleModeratePoulakou G, et al.2018-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of infections is murepavadin intended to treat?
Murepavadin is being developed for serious respiratory infections caused by Pseudomonas aeruginosa, specifically hospital‑acquired bacterial pneumonia and ventilator‑associated bacterial pneumonia, where multidrug‑resistant strains are common.
How does murepavadin differ from traditional antibiotics?
Unlike most antibiotics that inhibit cell‑wall synthesis or protein production, murepavadin binds to a unique outer‑membrane protein of P. aeruginosa, causing non‑lytic disruption of the bacterial envelope. This novel mechanism reduces the likelihood of cross‑resistance with existing drug classes.
Is murepavadin approved for clinical use?
No. Murepavadin remains an investigational agent. It has completed early phase‑1 pharmacokinetic and safety studies, but efficacy trials in infected patients and regulatory approval have not yet been achieved.
What are the known safety concerns?
Early studies report only mild, transient side effects. However, reduced renal function increases drug exposure substantially, so dose adjustments are recommended for patients with impaired kidneys. Comprehensive safety data in larger patient populations are still lacking.
Can murepavadin be given by inhalation?
Yes, inhaled (nebulized) delivery is being explored to achieve high drug concentrations directly in the lungs for pneumonia treatment. The intravenous route has been studied in phase‑1 trials, while inhaled formulations are still in development.
What is Murepavadin?
Murepavadin (also known as POL7080 or RG7929) is an investigational cyclic peptidomimetic antibiotic that selectively targets Pseudomonas aeruginosa. Developed for serious respiratory infections such as hospital‑acquired bacterial pneumonia and ventilator‑associated bacterial pneumonia, it belongs to a novel class of outer‑membrane protein‑targeting agents. Early clinical studies have explored both intravenous and inhaled delivery, aiming to address multidrug‑resistant (MDR) and extensively drug‑resistant (XDR) P. aeruginosa strains that limit current therapeutic options.
What is Murepavadin used for?
Murepavadin is educationally associated with: Treatment of MDR/XDR Pseudomonas aeruginosa infections, Inhaled therapy for pulmonary P. aeruginosa (e.g., cystic fibrosis), Treatment of Pseudomonas aeruginosa bloodstream infections, Ventilator-associated bacterial pneumonia (VABP), Hospital-acquired bacterial pneumonia (HABP), Treatment of Pseudomonas aeruginosa infections, Ventilator‑associated pneumonia caused by P. aeruginosa. Educational only — not medical advice.
How is Murepavadin administered?
Recorded routes of administration: Inhaled, Intravenous.
What are the potential side effects of Murepavadin?
Reported adverse effects include: Acute kidney injury / Nephrotoxicity, Headache, Acute kidney injury, Nausea, Elevated serum creatinine, Elevated liver enzymes, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Murepavadin?
Recorded contraindications: Known hypersensitivity to murepavadin or peptidomimetic components, Severe pre-existing renal impairment, Severe renal impairment, Concurrent use of nephrotoxic agents, Known hypersensitivity to murepavadin or its excipients. Consult a qualified clinician before use.